Why Is Ibogaine Illegal? The 1970 Schedule I Decision

When was ibogaine made illegal?

The date is exact, and it matters more than the usual “around 1970”.

Ibogaine is named in the text of the statute Congress passed. Schedule I(c) of the Comprehensive Drug Abuse Prevention and Control Act of 1970 lists seventeen hallucinogenic substances, and item 8 is a single word: Ibogaine. It sits between 4-methyl-2,5-dimethoxyamphetamine and lysergic acid diethylamide. The Act was signed on 27 October 1970. Ibogaine was not added later by agency rulemaking. It was in the bill.

It remains there today, at 21 CFR 1308.11(d)(21), DEA drug code 7260.

Three years earlier, in 1967, the Food and Drug Administration had already restricted it, using powers granted by the Drug Abuse Control Amendments of 1965, which allowed it to list substances with a potential for abuse. The context in both cases was a general federal retreat from psychedelics, not a finding about this molecule.

The order of events

The prohibition is therefore older than the evidence now offered to justify it, by thirty-nine years to the first published cardiac signal and forty-two to the mechanism. That does not make the prohibition wrong. It makes the usual explanation of it false.

One nuance the mortality literature adds, and that both camps tend to drop: the deaths cluster where the heart was already compromised, other substances were present, or nobody was watching. That is an argument for screening and monitoring rather than for prohibition, and it is equally an argument against the claim that ibogaine is safe in competent hands without either.

The three findings, examined

Schedule I placement rests on three statutory findings. Two are contestable and one is self-fulfilling.

High potential for abuse. Ibogaine produces a day of nausea, vomiting and near-total collapse. Recreational demand is negligible, there is no significant illicit market of the kind the abuse criterion was written for, and the LAPPA brief prepared for the federal Model Acts Program says plainly that ibogaine is not used recreationally or as a club drug.

No currently accepted medical use in the United States. True, and true in part because of the schedule. A Schedule I listing makes research harder, slower and more expensive; the absence of accepted medical use that results is then cited as grounds for the listing. This circular logic is a known feature of the Act, not something unique to this drug.

Lack of accepted safety under medical supervision. This is the finding that has aged into accuracy. In 1970 it was an assumption. Today the cardiac literature supports it, at least for administration without screening and monitoring.

Why other countries diverged

Ibogaine is not listed under the 1971 Convention on Psychotropic Substances. There is no treaty obligation to control it, and it is not on the World Health Organization’s list of substances under surveillance either, so it is not even in the pipeline for international review.

That single absence explains the map. Without an international requirement, each country decided for itself, at its own moment, usually by extending an existing rule rather than by considering ibogaine on its merits. Five regimes resulted, and the status by country table marks which entries we have read against the primary text and which we have not.

The last of the four is the most coherent and the least travelled. Canada reached it in 2017, after fatal adverse reaction reports, by adding ibogaine to its Prescription Drug List rather than to its drug schedules. That is the clearest example of a state treating ibogaine as a medicine whose problem is unsupervised use, rather than as a drug whose problem is existence.

The status by country table gives each jurisdiction and the instrument behind it.

What is moving now

More than at any point since 1970, and less than the headlines suggest.

At least eight US states have enacted ibogaine research legislation since mid-2025, and they do not all do what the coverage implies. Texas appropriated a reported $50 million, Arizona and Mississippi $5 million each. California, Oklahoma and Kentucky appropriate nothing: Kentucky’s $42 million was removed by committee substitute before the bill passed over the governor’s veto. Colorado went furthest of all, having decriminalised personal possession by ballot measure in 2022. None of them legalises anything, because no state can reschedule a federally controlled substance. The federal position sets out each instrument.

On 18 April 2026 the President signed Executive Order 14401, Accelerating Medical Treatments for Serious Mental Illness. Two of its provisions bear on this question.

It directs the Attorney General to open a rescheduling review once a product completes Phase 3 clinical trials for a serious mental health disorder, with rescheduling itself reserved for products ultimately approved. And it names ibogaine directly, ordering the FDA and DEA to build a Right to Try access pathway for eligible patients, including the Schedule I handling authorisations a treating physician would need.

The honest summary

Ibogaine is in Schedule I because of when it was noticed, not because of what was known about it. It stays there because the machinery for getting out requires clinical evidence that fifty years of prohibition made difficult to produce, and because the evidence that has since emerged about its cardiac effects gives regulators a reason not to hurry.

Both halves of that sentence are true at once. A reader who holds only the first concludes ibogaine is a victim of politics. A reader who holds only the second concludes the ban was always sound. The record supports neither on its own.